KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to 43.16%.

  • Aurinia Pharmaceuticals' EBITDA Margin rose 212800.0% to 43.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 29.15%, marking a year-over-year increase of 391300.0%. This contributed to the annual value of 2.48% for FY2024, which is 467500.0% up from last year.
  • Aurinia Pharmaceuticals' EBITDA Margin amounted to 43.16% in Q3 2025, which was up 212800.0% from 30.62% recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year EBITDA Margin high stood at 43.16% for Q3 2025, and its period low was 5511.27% during Q1 2021.
  • Its 5-year average for EBITDA Margin is 378.39%, with a median of 27.77% in 2023.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' EBITDA Margin soared by 1449332100bps in 2021, and later crashed by -90000bps in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' EBITDA Margin (Quarter) stood at 142.63% in 2021, then surged by 37bps to 89.96% in 2022, then soared by 34bps to 59.12% in 2023, then surged by 103bps to 1.95% in 2024, then surged by 2114bps to 43.16% in 2025.
  • Its last three reported values are 43.16% in Q3 2025, 30.62% for Q2 2025, and 37.09% during Q1 2025.